

7585 01 088 -4 2001

December 3, 2001

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane
Room 1061
Mail Stop HFA-305
Rockville, MD 20852

Re: Docket No. 01P-0428/CP 1

Supplemental Citizen Petition Regarding Proposed Generic Cefuroxime Axetil Products

Dear Sir or Madam:

SUPPLEMENTAL CITIZEN PETITION

We write to further supplement the Citizen's Petition filed on September 19, 2001 by Professional Detailing, Inc. and its wholly-owned affiliate LifeCycle Ventures (collectively, "PDI"), the exclusive distributor of CEFTIN® Tablets (cefuroxime axetil tablets) and CEFTIN® for Oral Suspension (cefuroxime axetil powder for oral suspension) in the United States. In its Petition, Docket No. 01P-0428/CP 1, PDI has requested that the Food and Drug Administration ("FDA"):

1. Decline to approve any Abbreviated New Drug Application ("ANDA") that seeks approval for a generic product containing a mixture of amorphous and crystalline cefuroxime axetil.
2. Decline to approve the pending ANDA submitted by Ranbaxy Laboratories, Inc. ("Ranbaxy"), in which Ranbaxy proposes to market a drug containing a mixture of amorphous and crystalline

01P-0428

SUP 2

2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19103-7301
215.851.8100
Fax 215.851.1420
Delaware
New Jersey
New York
Pennsylvania
United Kingdom
Virginia
Washington, DC

cefuroxime axetil as a generic substitute for CEFTIN®, which contains wholly amorphous cefuroxime axetil.

3. Decline to make effective any approval of the pending ANDA submitted by Ranbaxy or the pending ANDA submitted by Apotex, Inc. ("Apotex") for a generic drug containing a mixture of amorphous and crystalline cefuroxime axetil until either (a) thirty months from the date on which Glaxo commenced a patent infringement action against that applicant, or (b) the date on which a court enters a final order or judgment declaring Glaxo's U.S. Patent No. 4,562,181 to be invalid and/or not infringed by that applicant's ANDA.
4. Issue a regulation to set uniform standards for new drug applications in which the applicants seek approval for drugs that contain a different form of an active ingredient that is contained in a reference listed drug.

On October 16, 2001, PDI filed a Supplemental Citizen's Petition in which PDI discussed and attached major international pharmacopoeia monographs that provide further support for its Citizen's Petition. PDI appended to its October 16, 2001 Supplemental Citizen's Petition copies of the European, British and Chinese Pharmacopoeia monographs for cefuroxime axetil. In each case, the monograph provides that the drug substance must be in amorphous form and must have a specified isomeric mixture. None of these pharmacopoeial authorities permits the inclusion of crystalline material to this drug substance.


The Japanese Pharmacopoeia monograph for cefuroxime axetil similarly provides that the drug substance must be in amorphous form and have a specified isomeric mixture. (A copy of the Japanese Pharmacopoeia monograph is appended hereto as Exhibit 24.) PDI has filed this second supplement to its Citizen's Petition to bring the Japanese Pharmacopoeia reference to the Agency's attention.

Dockets Management Branch
December 3, 2001
Page 3

ReedSmith

For all the reasons set forth in its Citizen's Petition and the supplements thereto, PDI renews its request that FDA take the action described above.

Respectfully submitted,



William J. McNichol, Jr.
Marc J. Scheineson
Tracy Zurzolo Frisch
Reed Smith LLP
2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19103
Phone: 215.851.8100
Fax: 215.851.1420

Enclosure

cc: Ms. Jane A. Axelrad (w/enc.) (via overnight mail)
Mr. Gary J. Buehler (w/enc.) (via overnight mail)

**SUPPLEMENT II
TO
THE JAPANESE
PHARMACOPOEIA
THIRTEENTH EDITION**

Official from January 1, 2000

YAKUJI NIPPO, LTD.

This *English Version* of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic.

Supplement II to The Japanese Pharmacopoeia Thirteenth Edition

Copyright © 2000 by The Society of Japanese Pharmacopoeia

None of the contents of this publication may be reproduced by any means without the prior written permission of the publisher, YAKUJI NIPPO, LTD., 1, Kanda Izumicho, Chiyoda-ku, Tokyo, 101-8648 JAPAN; Tel: +81-3-3862-2141; Fax: +81-3-5821-8757.

ISBN4-8408-0588-1 C3047

Publisher: YAKUJI NIPPO, LTD.

Tel: +81-3-3862-2141

Fax: +81-3-5821-8757


Printed in Japan

ish white crystalline powder.

It is slightly soluble in water, very slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Add the following:

Cefteram Pivoxil



$C_{22}H_{27}N_9O_7S_2$: 593.64

Pivaloyloxymethyl (6*R*,7*R*)-7-[(*Z*)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(5-methyl-2*H*-tetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [82547-58-8, Cefteram]

Cefteram Pivoxil conforms to the requirements of Cefteram Pivoxil in the Requirements for Antibiotic Products of Japan.

Description Cefteram Pivoxil occurs as a white to yellowish white powder. It has a bitter taste.

It is freely soluble in methanol and in ethanol (95), slightly soluble in diethyl ether, and practically insoluble in water.

Ceftizoxime Sodium


Change the Description to read:

Description Ceftizoxime Sodium occurs as white to light yellow crystals or crystalline powder.

It is very soluble in water, slightly soluble in methanol, and practically insoluble in ethanol (95) and in diethyl ether.

Add the following:

Ceftriaxone Sodium



$C_{18}H_{16}N_8Na_2O_7S_3 \cdot 3\frac{1}{2}H_2O$: 661.61

Disodium (6*R*,7*R*)-7-[(*Z*)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(2,5-dihydro-2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-

5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hemiheptahydrate [104376-79-6]


Ceftriaxone Sodium conforms to the requirements of Ceftriaxone Sodium in the Requirements for Antibiotic Products of Japan.

Description Ceftriaxone Sodium occurs as a white to light yellowish white crystalline powder.

It is freely soluble in water, sparingly soluble in methanol, very slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Add the following:

Cefuroxime Axetil



$C_{20}H_{22}N_4O_{10}S$: 510.48

(*RS*)-1-Acetoxyethyl (6*R*,7*R*)-3-carbamoyloxymethyl-7-[2-(2-furyl)-2-[(*Z*)-methoxyimino]acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [64544-07-6]

Cefuroxime Axetil conforms to the requirements of Cefuroxime Axetil in the Requirements for Antibiotic Products of Japan.

Description Cefuroxime Axetil occurs as a white to yellowish white amorphous powder. It has a faint characteristic odor and a bitter taste.

It is freely soluble in 1,4-dioxane, soluble in methanol, sparingly soluble in ethanol (95), slightly soluble in diethyl ether, and very slightly soluble in water.

Cefuroxime Sodium

Change the Description to read:

Description Cefuroxime Sodium occurs as white to light yellowish white crystals or crystalline powder.

It is freely soluble in water, sparingly soluble in methanol, very slightly soluble in ethanol (95), and practically insoluble in diethyl ether.

Cetraxate Hydrochloride

Change the Identification (2) to read:

Identification

(2) Dissolve 0.5 g of Cetraxate Hydrochloride in 5 mL

QV
738
JJ3
N7
1996a
Suppl. 1

SUPPLEMENT I

REFERE

THESE JALPA KURSIN
PLAIRMAGOPOMIA
RETERENTYREPHON

Published in 1998 by
THE SOCIETY OF JAPANESE PHARMACOPOEIA

2-12-15, Shibuya, Shibuya-ku, Tokyo, 150-0002, JAPAN
Tel: +81-3-3400-5634; Fax: +81-3-3400-3158

Distributed by
YAKUJI NIPPO, LTD.
1, Kanda Izumicho, Chiyoda-ku, Tokyo, 101-8648, JAPAN

This edition is a reproduction of the English version of "the Supplement I to the Japanese Pharmacopoeia Thirteenth Edition" published by the Ministry of Health and Welfare.

Notice: This *English Version* of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic.

ISBN4-8408-0493-1 C3047


Printed in Japan

- Vitamin A Oil, 926
 Carbamazepine, 264
 Carbazochrome Sodium Sulfonate, 265
 Carbenicillin Sodium, 266
 Carbetapentane Citrate, 555
 Carbetapentene Citrate, 555
 Carbidopa, 266
 Carbocisteine, 267
 L-Carbocisteine, 267
 Carbolic Acid, 866
 for Disinfection, 867
 Liquefied, 867
 Carbon Dioxide, 268
 Carboxybenzylpenicillin Sodium, 266
 Carboxymethylcellulose, 751
 Calcium, 752
 Sodium, 752
 Cardamon, 751
 Carmellose, 751
 Calcium, 752
 Sodium, 752
 Carmofur, 269
 Carnauba Wax, 753
 Carteolol Hydrochloride, 270
 Cassia Seed, 754
 Castor Oil, 754
 Catalpa Fruit, 754
 Cefaclor, 270
 Cefadroxil, 271
 Cefalexin, 271
 Cefaloridine, 271
 Cefalotin Sodium, 271
 Cefamandole Sodium, 271
 Cefapirin Sodium, 272
 Cefazolin Sodium, 272
 Cefbuperazone Sodium, 272
 Cefmenoxime Hydrochloride, 272
 Cefmetazole Sodium, 272
 Cefoperazone Sodium, 273
 Cefotaxime Sodium, 273
 Cefotetan, 273
 Cefotiam Hydrochloride, 273
 Cefoxitin Sodium, 274
 Cefpiramide Sodium, 274
 Cefradine, 274
 Cefroxadine, 274
 Cefsulodin Sodium, 274
 Ceftizoxime Sodium, 275
 Cefuroxime Sodium, 275
 Cellulose
 Acetate Phthalate, 758
 Microcrystalline, 755
 Powdered, 758, 1129
 Cetanol, 759
 Cetraxate Hydrochloride, 759
 Chloral Hydrate, 275
 Chloramphenicol, 276
 Chlordiazepoxide, 277
 Powder, 278
 Tablets, 278
 Chlorhexidine
 Gluconate Solution, 279
 Hydrochloride, 280
 Chlorinated Lime, 760
 Chlormadinone Acetate, 281
 Chlorobutanol, 760
 Chlorphenesin Carbamate, 282
 Chlorpheniramine
 and Calcium Powder, 760
 Maleate, 283
 Maleate Injection, 283
 Maleate Powder, 284
 Maleate Tablets, 284
d-Chlorpheniramine Maleate, 285
 Chlorpromazine
 Hydrochloride, 286
 Hydrochloride Injection, 286
 Hydrochloride Tablets, 287, 1117
 Chlorpropamide, 287
 Tablets, 288
 Cholecalciferol, 289
 Cholera Vaccine, 761
 Cholesterol, 761
 Chorionic
 Gonadotrophin, 792
 Gonadotrophin for Injection, 794
 Ciclacillin, 290
 Ciclosporin, 290
 A, 290
 Cimetidine, 291
 Cimicifuga Rhizome, 762, 1130
 Cinchocaine Hydrochloride, 328
 Cinnamon
 Bark, 762, 1130
 Oil, 763
 Cinnarizine, 292
 Citric Acid, 292
 Anhydrous, 293
 Citrus Unshiu Peel, 763, 1130
 Clemastine Fumarate, 294
 Clindamycin Phosphate, 294
 Clinofibrate, 295
 Clozapramine Hydrochloride, 295
 Clofedanol Hydrochloride, 296
 Clofibrate, 297
 Capsules, 298
 Clomifene
 Citrate, 299
 Citrate Tablets, 299
 Clomipramine Hydrochloride, 300
 Clonazepam, 300
 Clonidine Hydrochloride, 301
 Clotiazepam, 302
 Clotrimazole, 303
 Clove, 763
 Oil, 764
 Powdered, 764
 Cloxacillin Sodium, 304
 Cloxazolam, 304
 CMC, 751
 Calcium, 752
 Sodium, 752
 Cnidium Rhizome, 764
 Cocaine Hydrochloride, 305
 Coconut Oil, 765
 Codeine
 Phosphate, 305
 Phosphate Powder, 1%, 306
 Phosphate Powder, 10%, 306
 Phosphate Tablets, 307
 Cod Liver Oil, 765
 Coix Seed, 765
 Colchicine, 308
 Colistin Sodium Methanesulfonate, 308
 Colophonium, 884
 Compound
 Acrinol and Zinc Oxide Oil, 724
 Diastase and Sodium Bicarbonate Powder, 772
 Hycodone Injection, 852
 Iodine Glycerin, 808
 Methyl Salicylate Spirit, 834
 Oxycodone and Atropine Injection, 853
 Oxycodone Injection, 852
 Phellodendron Powder for Cataplasm, 865
 Prostaglandin E₁ α -Cyclodextrin Clathrate, 194
 Rhubarb and Senna Powder, 883
 Salicylic Acid Spirit, 888
 Scopolia Extract and Diastase Powder, 892
 Scopolia Extract and Tannic Acid Ointment, 894
 Scopolia Extract and Tannic Acid Suppositories, 894
 Thianthol and Salicylic Acid Solution, 919
 Vitamin B Powder, 927
 Concentrated
 Glycerin, 413
 Glycerol, 413
 Condurango, 766
 Fluidextract, 766
 Coptis Rhizome, 766, 1130
 Corn
 Oil, 768
 Starch, 768
 Cornus Fruit, 768
 Cortisone
 Acetate, 308
 Acetate Injection (Aqueous Suspension), 309
 Corydalis Tuber, 769
 Cotton, Absorbent, 715, 1129
 Cream, Bufexamac, 248
 Creosote, 769
 Cresol, 769
 Solution, 769
 Croconazole Hydrochloride, 310
 Crude Glycyrrhiza Extract, 792
 Crystalline
 Insulin Zinc Injection (Aqueous Suspension), 449

TRACY Z FRISCH
(215) 241-8186
REEDSMITH LLP
2500 ONE LIBERTY PLACE
PHILADELPHIA PA 19103-7301

LTR 1 OF 1

SHIP TO:
MAIL STOP HFA-305
DOCKETS MANAGEMENT BRANCH
ROOM 1061
5630 FISHERS LANE
ROCKVILLE MD 20852



MD 207 9-04



UPS NEXT DAY AIR

TRACKING #: 1Z 733 2X6 01 4156 8724

1



BILLING: P/P

REF 1: 852911/20009/4065

UOM 3.1 2 UPS Thur 11.0A 11/2000

and/or conditions established by the Convention for the Unification of Certain Rules Relating to International Carriage by Air (the "Warsaw Convention") and/or the Convention on the Contract for the International